BRIA
SCPH

Balanced Rock Investment Advisors’s scPharmaceuticals SCPH Stock Holding History

Balanced Rock Investment Advisors’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83,133
Closed -$471K – 95
2025
Q3 		$471K Sell
83,133
-7,835
-9% -$40.1K 0.34% 63
2025
Q2 		$347K Buy
90,968
+19,768
+28% +$61.4K 0.27% 76
2025
Q1 		$187K Buy
71,200
+838
+1% +$2.73K 0.15% 86
2024
Q4 		$249K Buy
70,362
+5,612
+9% +$21.5K 0.2% 79
2024
Q3 		$295K Buy
64,750
+1,620
+3% +$7.84K 0.23% 73
2024
Q2 		$275K Buy
63,130
+5,882
+10% +$25.8K 0.23% 71
2024
Q1 		$287K Buy
57,248
+4,827
+9% +$27K 0.25% 75
2023
Q4 		$329K Buy
+52,421
New +$300K 0.29% 75

Balanced Rock Investment Advisors's SCPH Position: Q4 2025 in Review

Balanced Rock Investment Advisors sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 83,133 shares — an estimated $471K sold.

Balanced Rock Investment Advisors first reported a position in SCPH in Q4 2023 and held it in 8 quarters. The position peaked at $471K in Q3 2025. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

  • Balanced Rock Investment Advisors reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Balanced Rock Investment Advisors sold 83,133 scPharmaceuticals shares in Q4 2025, an estimated $471K.
  • Balanced Rock Investment Advisors first reported a position in scPharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Balanced Rock Investment Advisors's scPharmaceuticals position peaked at $471K in Q3 2025.
  • 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Balanced Rock Investment Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.